Trial Profile
Safety, tolerability, pharmacokinetics, and efficacy of single inhaled administrations of trospium chloride inhalation powder (TrIP) in patients with chronic obstructive pulmonary disease.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jul 2011
Price :
$35
*
At a glance
- Drugs Trospium chloride (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- 15 Jul 2011 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
- 27 Sep 2007 Positive interim results have been announced by Alkermes and Indevus.
- 10 Jul 2007 New trial record.